Contributions
Abstract: PB1559
Type: Publication Only
Session title: Hodgkin lymphoma - Clinical
Background
Early disease progression within two years of diagnosis (POD24) is linked to poor overall survival (OS) in follicular lymphoma but its prognostic role is less clear in Hodgkin lymphoma (HL).
Aims
In this study, we wanted to identify the prognostic factors associated with early progression of HL and to determine its impact on patient survival and outcome.
Methods
We analyzed the impact of POD 24 of patients followed for HL in our department, and who received initially ABVD, with or without radiotherapy. This study involved 96 patients followed between 2002 and 2012. We excluded from the analysis patients who, within 24 months of starting treatment, died without progression or were lost of follow-up without prior progression. OS was calculated from progression ( for patients with early progression), and from 24 months after initiation of treatment for those without progression.
Results
Early progression was observed in 28 (29%) patients. The 10-year OS of patients with POD24 was 18%, while that of patients without early progression was 80% (p <0.0001). POD24 was correlated with the existence of an extranodal localization (p = 0.0008), an extended stage of the disease (p = 0.02), B symptoms (p = 0.02), as well as hypoalbuminemia (p = 0.04). The rate of relapses was higher in patients with POD24 (32%), compared to patients without POD (10%, p = 0.02). In multivariate analysis, two factors were predictive for the long-term survival of the patients: extranodal localization (p = 0.03), and POD24 (p <0.0001).
Conclusion
In patients with HL who have received first-line treatment, early disease progression is associated with poorer survival , and POD24 may represent a useful endpoint in future prospective clinical trials or assessments of responses. to treatment .
Keyword(s): Hodgkin's lymphoma, Progression, Survival prediction
Abstract: PB1559
Type: Publication Only
Session title: Hodgkin lymphoma - Clinical
Background
Early disease progression within two years of diagnosis (POD24) is linked to poor overall survival (OS) in follicular lymphoma but its prognostic role is less clear in Hodgkin lymphoma (HL).
Aims
In this study, we wanted to identify the prognostic factors associated with early progression of HL and to determine its impact on patient survival and outcome.
Methods
We analyzed the impact of POD 24 of patients followed for HL in our department, and who received initially ABVD, with or without radiotherapy. This study involved 96 patients followed between 2002 and 2012. We excluded from the analysis patients who, within 24 months of starting treatment, died without progression or were lost of follow-up without prior progression. OS was calculated from progression ( for patients with early progression), and from 24 months after initiation of treatment for those without progression.
Results
Early progression was observed in 28 (29%) patients. The 10-year OS of patients with POD24 was 18%, while that of patients without early progression was 80% (p <0.0001). POD24 was correlated with the existence of an extranodal localization (p = 0.0008), an extended stage of the disease (p = 0.02), B symptoms (p = 0.02), as well as hypoalbuminemia (p = 0.04). The rate of relapses was higher in patients with POD24 (32%), compared to patients without POD (10%, p = 0.02). In multivariate analysis, two factors were predictive for the long-term survival of the patients: extranodal localization (p = 0.03), and POD24 (p <0.0001).
Conclusion
In patients with HL who have received first-line treatment, early disease progression is associated with poorer survival , and POD24 may represent a useful endpoint in future prospective clinical trials or assessments of responses. to treatment .
Keyword(s): Hodgkin's lymphoma, Progression, Survival prediction